Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20366 (
substance P
)
21,176
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, we examined the expression of neurotrophins in mouse lymphocytes and the regulation of their expression by mitogens and neurotransmitters. We found that mixed splenocytes as well as T and B lymphocytes expressed mRNA for all the neurotrophins examined. Differential regulation of the neurotrophins was obtained upon stimulation of the cells. Thus, LPS increased the expression of
NGF
, BDNF and NT-3 in splenocytes and B cells, whereas Con-A increased the mRNA of NT-3 and NT-4 in T cells and
NGF
expression in splenocytes. The neurotransmitter
substance P
and the beta-adrenergic agonist, isoproterenol induced an increase in the expression of
NGF
. Our results suggest an important role for the different neurotrophins in the function of the immune system and point to a bi-directional interaction between neurotrophins and neurotransmitters in this system.
...
PMID:Differential regulation of neurotrophin expression by mitogens and neurotransmitters in mouse lymphocytes. 1069 6
Reverse transcription-polymerase chain reaction using 32P-labeled dCTP with specific primers for putative neurotransmitters related and neuronal growth-related genes (GAP-43,
NGF
and BDNF) were used to search for evidence of such substances in the Merkel cell. Merkel cell samples were made from sinus hairs in the facial skin of rats. The relative amount of mRNA in a tissue sample concentrated in Merkel cells was compared semiquantitatively to that from nearby tissue without Merkel cells. mRNAs for VIP, tyrosine hydroxylase,
substance P
were found in higher concentration in Merkel cells than in control tissues. mRNA for genes encoding pro-enkephalin, GAP-43, CGRP,
NGF
and BDNF were detected in the Merkel cell samples at concentration statistically equivalent to those found in the control tissues. It was concluded that the relative concentration of mRNAs for VIP, tyrosine hydroxylase and
substance P
is consistent with the possibility that Merkel cell acts as a possible transduction element in mechanical excitation of sense organs in which Merkel cells are present.
...
PMID:Expressions of putative neurotransmitters and neuronal growth related genes in Merkel cell-neurite complexes of the rats. 1079 95
Brain-derived neurotrophic factor (BDNF) is synthesized by small neuron cell bodies in the dorsal root ganglia (DRG) and is anterogradely transported to primary afferent terminals in the dorsal horn where it is involved in the modulation of painful stimuli. Here we show that BDNF is released in the rat isolated dorsal horn after chemical stimulation by capsaicin or electrical stimulation of dorsal roots. Capsaicin superfusion (1-100 microm) induced a dose-dependent release of BDNF, measured using ELISA. The highest dose of capsaicin also induced a depletion of BDNF protein in the dorsal horn. BDNF release was also seen after electrical stimulation of the dorsal roots at C-fiber strength. This release was encoded by specific patterns of afferent fiber stimulation. Neither continuous low-frequency (480 pulses, 1 Hz) nor tetanic high-frequency (300 pulses in 3 trains, 100 Hz) stimulation evoked release of BDNF, although
substance P
(SP) release was observed under both of these conditions. However, BDNF was released after short bursts of high-frequency stimulation (300 pulses in 75 trains, 100 Hz) along with SP and glutamate. The NMDA antagonist d-AP-5 inhibited electrically evoked BDNF release. BDNF release was also measured after systemic or intrathecal
NGF
treatment. This upregulated BDNF content in the DRG and increased the capsaicin-evoked release of BDNF. Similarly, the amount of BDNF released by burst stimulation was increased after
NGF
treatment. This activity-dependent release continued to be encoded solely by this stimulation pattern. These experiments demonstrate that BDNF release in the dorsal horn is encoded by specific patterns of afferent fiber stimulation and is mediated by NMDA receptor activation.
...
PMID:Brain-derived neurotrophic factor is released in the dorsal horn by distinctive patterns of afferent fiber stimulation. 1140 34
Dorsal root ganglion (DRG) neurons that mediate nociception express the high affinity NGF receptor (trkA) gene and the
preprotachykinin
(
PPT
) gene.
NGF
has been shown to regulate both of these DRG neuronal genes. Our laboratory has shown that these genes are also regulated by estrogen. Long-term daily estrogen replacement, in adult ovariectomized (OVX) rats, causes a coordinate decline in trkA and beta-
PPT
mRNA levels in lumbar DRG neurons, while short-term estrogen replacement increases trkA mRNA levels in uninjured as well as in axotomized lumbar DRG neurons. The purpose of the current study was to test the hypothesis that short-term estrogen replacement increases DRG beta-
PPT
mRNA levels in lumbar DRG neurons of OVX rats and that the increase is dependent on target-derived
NGF
. Sciatic nerve transection (SNT) was used to eliminate target-derived
NGF
in L4 and L5 DRGs in adult OVX rats. Seven days later, one-half of the SNT and one-half of the animals that had received sham sciatic nerve transactions (SHAM) received two daily injections of estradiol benzoate (EB). The remaining rats received two daily injections of vehicle alone. Quantitative in situ hybridization analyses of sections from L4 and L5 DRGs showed that two daily injections of EB significantly increased beta-
PPT
mRNA levels in DRGs of SHAM animals, but had no effect on beta-
PPT
mRNA levels in DRGs from SNT animals. These data coupled with our earlier observations of the effect of short-term estrogen replacement on DRG trkA mRNA levels, indicate that the regulation of DRG beta-
PPT
mRNA levels by estrogen requires target-derived
NGF
.
...
PMID:Short-term estrogen replacement increases beta-preprotachykinin mRNA levels in uninjured dorsal root ganglion neurons, but not in axotomized neurons. 1142 87
We have examined whether delayed exogenous
NGF
administered to an axotomised peripheral nerve reverses the increased transganglionic choleragenoid (CTB) labelling in lamina II. Two, four, eight or 18 weeks after bilateral sciatic nerve section,
NGF
was applied unilaterally for an additional 2-week period to the transected nerve stump. The transganglionic choleragenoid labelling and
substance P
(SP) expression were determined and compared to the contralateral axotomised side in the spinal cord dorsal horn. Delayed
NGF
administration reversed the transganglionic choleragenoid labelling in lamina II when administered 2 or 18 weeks after the sciatic nerve lesion, but not at 4 or 8 weeks. There was also a clear recovery of SP on the axotomised,
NGF
-treated side 2 or 18 weeks after the sciatic nerve lesion, but not at the intermediate survival times. At the longer survival time, however, there was a recovery of SP regardless of
NGF
treatment. These results suggest that there is a critical window as to when
NGF
administration can be effective in reversing axotomy-induced changes in the spinal cord.
...
PMID:Delayed administration of NGF reverses nerve injury induced central alterations of primary afferents. 1143 19
Neurotransmitter expression can be regulated by both activity and neurotrophins in a number of in vitro systems. We examined whether either of these factors was likely to play a role in the in vivo optic nerve-dependent regulation of a
substance P
-like immunoreactive (SP-ir) population of cells in the developing optic tectum of the frog. In contrast to our previous results with the adult system, blocking tectal cell responses to glutamate release by retinal ganglion cells with 6-cyano-7-nitroquinoxaline-2,3 dione (CNQX) did not affect the percent of SP-ir cells in the developing tectum. Treatment with d-(-)-2-amino-5-phosphonovaleric acid (d-AP-5) was also ineffective in this regard, although both it and CNQX treatment disrupted visual map topography. Chronic treatment with brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5) produced increases in SP-ir cells in the treated lobes of normal animals, which were significant in the case of NT-4/5. Both substances also prevented the decrease of SP cells that would otherwise occur in the deafferented lobe of unilaterally optic nerve-transected tadpoles. These changes in the percent of SP-ir cells occurred without any detectable changes in the overall number of tectal cells.
NGF
had no effect on SP expression. Nor did it affect topographic map formation, which was disrupted by treatment with either BDNF or NT-4/5. Our results demonstrate that different mechanisms regulate SP expression in the developing and adult tectum. They indicate that neurotrophin levels in the developing optic tectum may selectively regulate a specific neuropeptide-expressing population of cells.
...
PMID:Neurotrophins, but not depolarization, regulate substance P expression in the developing optic tectum. 1143 42
1. Nerve growth factor induces an airway hyperresponsiveness in vivo in guinea-pigs, as we have shown previously. Since antagonizing the neurokinin-1 (NK(1)) receptor can prevent this
NGF
-induced airway hyperresponsiveness and since sensory nerves release tachykinins, we investigated the role of sensory nerves in the
NGF
-induced airway hyperresponsiveness. 2. We used isolated tracheal rings from guinea-pigs to measure tracheal contractility. In these rings sensory nerve endings are present, but these endings lack any contact with their cell bodies. 3. In this in vitro system,
NGF
dose-dependently induced a tracheal hyperresponsiveness to histamine. The NK(1) receptor antagonist SR140333 could block the induction of tracheal hyperresponsiveness. 4. To further investigate the involvement of sensory nerve endings we used the cannabinoid receptor 1 (CB(1)) agonist R-methanandamide to inhibit excitatory events at the nerve terminal. The CB(1) receptor agonist was capable of blocking the tracheal hyperresponsiveness to
NGF
in the isolated system, as well as the airway hyperresponsiveness to
NGF
in vivo. 5. This indicates that
NGF
can induce an increase in airway responsiveness in the absence of sensory nerve cell bodies.
NGF
may act by increasing
substance P
release from sensory nerve endings, without upregulation of
substance P
in the neurons.
Substance P
in its turn is responsible for the induction of the
NGF
-induced airway hyperresponsiveness.
...
PMID:The role of sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea-pigs. 1160 17
NGF
increases expression and content of
substance P
in developing and mature spinal sensory neurons. The role this neurotrophin plays in peptide release, however, is less clear. Accordingly, we examined
substance P
release from cultures of mature rat sensory neurons, which do not require
NGF
for survival. Neurons grown without
NGF
have a low but detectable basal release, which increases with depolarization by KCI (50 mM) but never achieves statistical significance. In contrast, basal release is 3 times higher from neurons that have been cultured in the presence of
NGF
, and KCl depolarization triples the amount of SP released. Stimulation with capsaicin (10(-7) M) yields similar results. Residual peptide remaining after capsaicin stimulation is refractory to release for up to 24 h. Bradykinin does not induce SP secretion from mature neurons nor does it potentiate the action of capsaicin. GDNF, which also increases SP content, mimics
NGF
. Addition of
NGF
to the bath during release does not directly induce SP secretion, nor does it alter the effects of KCI, capsaicin, or bradykinin. It appears therefore that
NGF
increases SP release indirectly by increasing intracellular stores.
...
PMID:Nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) regulate substance P release in adult spinal sensory neurons. 1271 37
Increased expression of
NGF
after spinal cord injury induces sprouting of primary nociceptive axons. Exogenous application of
NGF
also results in extensive sprouting of these axons and causes chronic pain in uninjured animals. During development, semaphorin3A is thought to act as a repulsive guidance cue for
NGF
-responsive nociceptive afferents, restricting their projections to the superficial dorsal horn. We investigated the ability of semaphorin3A to selectively reduce
NGF
-induced sprouting and neuropathic pain in adult rats. The chemorepulsive effect of virus-mediated semaphorin3A expression was shown to counteract the sprouting induced by
NGF
in a dose-dependent manner, both in vitro and in adult rat spinal cords. Coexpression of semaphorin3A and
NGF
at moderate to low concentrations within the adult spinal cord reduced sprouting of calcitonin gene-related peptide and
substance P
-containing axons compared with GFP and
NGF
coexpression controls. At high expression levels of
NGF
, there was no difference in sprouting between the semaphorin3A-treated and control groups. The distribution of endogenous primary nociceptive afferents in the spinal cord appeared to be unaffected by semaphorin3A treatment in these experiments. Behavioral assessment shows that semaphorin3A coexpression with
NGF
led to decreased mechanical allodynia but no significant reductions in thermal hyperalgesia. These findings demonstrate directly that mature sensory afferents maintain their responsiveness to semaphorin3A, suggesting that this molecule might be used therapeutically to control aberrant sensory sprouting involved in pain or autonomic dysfunction.
...
PMID:Semaphorin3A inhibits nerve growth factor-induced sprouting of nociceptive afferents in adult rat spinal cord. 1474 26
Vernal keratoconjunctivitis (VKC) is an allergic eye disease that especially affects young boys. The most common symptoms are itching, photophobia, burning, and tearing. The most common signs are giant papillae, superficial keratitis, and conjunctival hyperaemia. Patients with VKC frequently have a family or medical history of atopic diseases, such as asthma, rhinitis, and eczema. However, VKC is not associated with a positive skin test or RAST in 42-47% of patients, confirming that it is not solely an IgE-mediated disease. On the basis of challenge studies as well as immunohistochemical and mediator studies, a Th2-driven mechanism with the involvement of mast cells, eosinophils, and lymphocytes has been suggested. Th2 lymphocytes are responsible for both hyperproduction of IgE (interleukin 4, IL-4) and for differentiation and activation of mast cells (IL-3) and eosinophils (IL-5). Other studies have demonstrated the involvement of neural factors such as
substance P
and
NGF
in the pathogenesis of VKC, and the overexpression of oestrogen and progesterone receptors in the conjunctiva of VKC patients has introduced the possible involvement of sex hormones. Thus, the pathogenesis of VKC is probably multifactorial, with the interaction of the immune, nervous, and endocrine systems. The clinical management of VKC requires a swift diagnosis, correct therapy, and evaluation of the prognosis. The diagnosis is generally based on the signs and symptoms of the disease, but in difficult cases can be aided by conjunctival scraping, demonstrating the presence of infiltrating eosinophils. Therapeutic options are many, in most cases topical, and should be chosen on the basis of the severity of the disease. The most effective drugs, steroids, should however be carefully administered, and only for brief periods, to avoid secondary development of glaucoma.A 2% solution of cyclosporine in olive oil or in castor oil should be considered as an alternative. The long-term prognosis of patients is generally good; however 6% of patients develop corneal damage, cataract, or glaucoma.
...
PMID:Vernal keratoconjunctivitis. 1506 27
<< Previous
1
2
3
4
5
6
7
Next >>